Innate Pharma (IPHA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $156.94M
Last updated: Nov 17, 2026 at 4:10 PM ET
Innate Pharma (IPHA) Stock Chart
Innate Pharma (IPHA) has a latest price of $1.33 on Nov 17, 2026, 50.9% below its 52-week high of $2.71. Its price fell 26.9% over the past 12 months. The month-end price fell 74.8% over the 5 years through Oct 2026, a compound annual decline of 24.1%.
Price Chart
From Oct 2019 to Oct 2026, its highest month-end close was $7.60 in Apr 2020 and its lowest $1.28 in Mar 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart IPHA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for IPHA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 37.3%, and over 6 months it fell 34.5%. The month-end price fell 40.9% over the 3 years through Oct 2026, a compound annual decline of 16.1%.
| Period | Change |
|---|---|
| 1 month | -8.9% |
| 3 months | -37.3% |
| 6 months | -34.5% |
| 12 months | -26.9% |
| 12 months, with dividends | -26.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -40.9% | -16.1% |
| 5 years | -74.8% | -24.1% |
Price by Year
Its best calendar year was 2021, when the price rose 11.5%, and its weakest was 2020, when it fell 36.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.46 | -16.6% |
| 2025 | $1.75 | -4.9% |
| 2024 | $1.84 | -34.3% |
| 2023 | $2.80 | -24.9% |
| 2022 | $3.73 | -18.2% |
| 2021 | $4.56 | +11.5% |
| 2020 | $4.09 | -36.5% |
Trading Range
The price is 16.3% below its 50-day average of $1.59 and 21.4% below its 200-day average of $1.69.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.33 | |
| 52-week high | $2.71 | -50.9% |
| 52-week low | $1.17 | +13.7% |
| 50-day average | $1.59 | -16.3% |
| 200-day average | $1.69 | -21.4% |
Price Risk
Over 3 years, its largest fall from a peak was 61.3%.
| Measure | Value |
|---|---|
| 1-year beta | 1.30 |
| Largest fall, 1 year | -47.5% |
| Largest fall, 3 years | -61.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About IPHA
What is IPHA's 1-year price change?
Innate Pharma's price fell 26.9% over the past 12 months. With dividends included, the 12-month total return was -26.9%.
What is IPHA's 5-year price change?
Innate Pharma's month-end price fell 74.8% over the 5 years through Oct 2026, a compound annual decline of 24.1%. These figures leave out dividends.
What is IPHA's 52-week high and low?
Innate Pharma's 52-week high is $2.71 and its 52-week low is $1.17. Its latest price of $1.33 on Nov 17, 2026 is 50.9% below the high.
What is IPHA's beta?
Innate Pharma's 1-year beta against the S&P 500 is 1.30, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 47.5%.
Is the IPHA chart free?
Yes. Advanced Charting for IPHA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
IPHA pages: Overview, Charting, Financials